Tempus AI (TEM) Secures FDA Clearance For ECG-Low EF Software
Summary
Tempus AI secured FDA clearance for its ECG-Low EF software, strengthening its position in AI-driven precision medicine. The company also expanded its collaboration with Personalis to improve colorectal cancer detection. These developments support Tempus AI’s product differentiation and may help drive future revenue growth. The article also notes that the company’s stock has performed well recently, alongside broader market strength.
Classifications
industries
HealthTech
applications
AI & Machine learning
AskAI Classifications
Labels
Healthcare Software
Precision Medicine
AI-enabled Software
Linked Companies
Tempus
$1M to $5M